## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($210.66)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Did IQVIAâ€™s (IQV) Debt Refinancing and Lower SOFR Costs Just Shift Its Investment Narrative?**
- Source: Simply Wall Street | 20251214T180826 | Somewhat-Bullish | Relevance: 100%
- IQVIA Holdings recently refinanced its credit facilities, simplifying its capital structure and reducing borrowing costs by eliminating the SOFR credit spread adjustment for some US dollar borrowings. This move aims to free up cash flow for its global operations and slightly eases concerns about high leverage, impacting its investment narrative. Investors should monitor how IQVIA converts its R&D Solutions backlog into profit growth amidst competitive market conditions.

**2. Avoiding Lag: Real-Time Signals in (IQV) Movement**
- Source: Stock Traders Daily | 20251210T061000 | Somewhat-Bearish | Relevance: 100%
- This article discusses real-time AI-generated trading signals for Iqvia Holdings Inc. (NYSE: IQV), highlighting a potential weak near-term sentiment and a mid-channel oscillation pattern. It presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, offering targets and stop-loss levels. The analysis emphasizes an exceptional risk-reward short setup with significant downside potential versus limited risk, alongside multi-timeframe signal analysis.

**3. Lazard Asset Management LLC Acquires 107,500 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251214T134208 | Bullish | Relevance: 100%
- Lazard Asset Management LLC increased its stake in IQVIA Holdings Inc. by 6.1%, now owning 1,866,537 shares valued at approximately $294.1 million. The medical research company recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts with an average price target of $241.82.

**4. Bank of Nova Scotia Increases Stock Holdings in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251211T220754 | Bullish | Relevance: 100%
- Bank of Nova Scotia significantly increased its stake in IQVIA Holdings Inc. by 102.3% in Q2, boosting its holdings to 53,969 shares valued at $8.51 million. This increase aligns with analysts' "Moderate Buy" consensus and an average price target of $241.44 for IQVIA, following strong Q3 earnings and positive FY2025 guidance. Other institutional investors also adjusted their positions in the medical research company.

**5. Jump Financial LLC Lowers Holdings in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251211T070826 | Somewhat-Bullish | Relevance: 100%
- Jump Financial LLC reduced its stake in IQVIA Holdings Inc. by 31.6% in the second quarter, selling 18,692 shares and ending with 40,508 shares valued at approximately $6.38 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" consensus with an average target price of $241.44. IQVIA also slightly surpassed quarterly earnings expectations and provided a positive FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $5.8M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.2 |
| Current P/E | 18.7 |
| YoY Growth | 8.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.23x) but short-term weakness (below SMA20). MACD histogram bearish (-1.08), momentum weakening. RSI neutral at 51. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.16% (CS: 28) | Neutral |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | -1.08 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 1.027x | Above |
| vs SMA200 | 1.226x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $222.26
- **Stop Loss:** $210.66 (5.2% risk)
- **Target:** $245.46 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $19,114.36
- **Portfolio %:** 19.11%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*